文献速递心血管MR

轻链型心脏淀粉样变性:心脏磁共振评估化疗反应

Light-Chain Cardiac Amyloidosis: Cardiac Magnetic Resonance for Assessing Response to Chemotherapy.
PubMed 文献 · Korean J Radiol · 2024-01-01

这项前瞻性研究纳入111例轻链型心脏淀粉样变性患者,纵向用生物标志物和心脏磁共振监测化疗反应。化疗后心肌T2升高、右心室纵向应变恢复、右心室细胞外容积分数降低,且在反应优组更明显;反应优组右心室和左心室细胞外容积分数降低幅度均显著大于反应差组。心脏磁共振可用于监测组织特征和心室功能恢复。

要点

  • 化疗后右心室细胞外容积分数降低更明显,可能更早反映淀粉样沉积消退。
  • 反应优组右心室和左心室细胞外容积分数降低幅度均显著大于反应差组。
  • 化疗后心肌T2升高、右心室纵向应变恢复,右心室变化更显著。

核心结论

  • 轻链型心脏淀粉样变性患者化疗后心脏淀粉样沉积可消退,右心室可能更早、更明显;心脏磁共振可有效监测组织特征和心室功能恢复,支持用于治疗反应评估。

研究设计与样本

  • 前瞻性研究,纳入111例轻链型心脏淀粉样变性患者(男性50.5%,中位年龄54岁,四分位距49-63岁),纵向用生物标志物和心脏磁共振监测,化疗后按血液学和心脏实验室反应分为反应优组和反应差组。

关键影像表现/征象

  • 化疗后(前 vs 后)心肌T2升高(43.6 ± 3.5 ms vs 44.6 ± 4.1 ms;P = 0.008)。
  • 化疗后右心室纵向应变恢复(中位数 -9.6% vs -11.7%;P = 0.031)。
  • 化疗后右心室细胞外容积分数降低(中位数 53.9% vs 51.6%;P = 0.048)。
  • 上述变化在反应优组更明显。

诊断标准与关键数值

  • 心脏实验室反应优组右心室细胞外容积分数降低 -2.9%(四分位距 -8.7%-1.1%)vs 反应差组 1.7%(四分位距 -5.5%-7.1%);P = 0.017。
  • 心脏实验室反应优组左心室细胞外容积分数降低 -2.0%(四分位距 -6.0%-1.3%)vs 反应差组 2.0%(四分位距 -3.0%-5.0%);P = 0.01。

临床应用与阅片要点

  • 化疗后随访心脏磁共振时,可关注右心室细胞外容积分数和纵向应变的变化,其改变可能早于左心室。
  • 评估治疗反应时需结合血液学和心脏实验室反应分组,反应优组细胞外容积分数降低更显著。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Cardiac magnetic resonance (CMR) is a diagnostic tool that provides precise and reproducible information about cardiac structure, function, and tissue characterization, aiding in the monitoring of chemotherapy response in patients with light-chain cardiac amyloidosis (AL-CA). This study aimed to evaluate the feasibility of CMR in monitoring responses to chemotherapy in patients with AL-CA.

MATERIALS AND METHODS: In this prospective study, we enrolled 111 patients with AL-CA (50.5% male; median age, 54 [interquartile range, 49-63] years). Patients underwent longitudinal monitoring using biomarkers and CMR imaging. At follow-up after chemotherapy, patients were categorized into superior and inferior response groups based on their hematological and cardiac laboratory responses to chemotherapy. Changes in CMR findings across therapies and differences between response groups were analyzed.

RESULTS: Following chemotherapy (before vs. after), there were significant increases in myocardial T2 (43.6 ± 3.5 ms vs. 44.6 ± 4.1 ms; P = 0.008), recovery in right ventricular (RV) longitudinal strain (median of -9.6% vs. -11.7%; P = 0.031), and decrease in RV extracellular volume fraction (ECV) (median of 53.9% vs. 51.6%; P = 0.048). These changes were more pronounced in the superior-response group. Patients with superior cardiac laboratory response showed significantly greater reductions in RV ECV (-2.9% [interquartile range, -8.7%-1.1%] vs. 1.7% [-5.5%-7.1%]; P = 0.017) and left ventricular ECV (-2.0% [-6.0%-1.3%] vs. 2.0% [-3.0%-5.0%]; P = 0.01) compared with those with inferior response.

CONCLUSION: Cardiac amyloid deposition can regress following chemotherapy in patients with AL-CA, particularly showing more prominent regression, possibly earlier, in the RV. CMR emerges as an effective tool for monitoring associated tissue characteristics and ventricular functional recovery in patients with AL-CA undergoing chemotherapy, thereby supporting its utility in treatment response assessment.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Guo Y, Li X, Gao Y, et al. Light-Chain Cardiac Amyloidosis: Cardiac Magnetic Resonance for Assessing Response to Chemotherapy. Korean J Radiol. 2024. PMID: 38685733. doi:10.3348/kjr.2023.0985

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。